90 related articles for article (PubMed ID: 18225541)
1. Pamidronate down-regulates urokinase-type plasminogen activator expression in PC-3 prostate cancer cells.
Iguchi K; Tatsuda Y; Usui S; Hirano K
Anticancer Res; 2007; 27(6B):3843-8. PubMed ID: 18225541
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase C is inhibited by bisphosphonates in prostate cancer PC-3 cells.
Tatsuda Y; Iguchi K; Usui S; Suzui M; Hirano K
Eur J Pharmacol; 2010 Feb; 627(1-3):348-53. PubMed ID: 19903468
[TBL] [Abstract][Full Text] [Related]
3. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
Yoshida E; Verrusio EN; Mihara H; Oh D; Kwaan HC
Cancer Res; 1994 Jun; 54(12):3300-4. PubMed ID: 8205553
[TBL] [Abstract][Full Text] [Related]
5. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of caveolin-1 expression by incadronate in PC-3 prostate cells.
Iguchi K; Matsunaga S; Nakano T; Usui S; Hirano K
Anticancer Res; 2006; 26(4B):2977-81. PubMed ID: 16886623
[TBL] [Abstract][Full Text] [Related]
7. Pamidronate inhibits antiapoptotic bcl-2 expression through inhibition of the mevalonate pathway in prostate cancer PC-3 cells.
Iguchi K; Tatsuda Y; Usui S; Hirano K
Eur J Pharmacol; 2010 Sep; 641(1):35-40. PubMed ID: 20519142
[TBL] [Abstract][Full Text] [Related]
8. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
Tanabe T
Hiroshima J Med Sci; 2000 Mar; 49(1):67-72. PubMed ID: 10824459
[TBL] [Abstract][Full Text] [Related]
9. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
Warnecke-Eberz U; Prenzel KL; Baldus SE; Metzger R; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
[TBL] [Abstract][Full Text] [Related]
10. Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors.
Helenius MA; Savinainen KJ; Bova GS; Visakorpi T
BJU Int; 2006 Feb; 97(2):404-9. PubMed ID: 16430655
[TBL] [Abstract][Full Text] [Related]
11. Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: role of epigenetic mechanisms.
Hagelgans A; Menschikowski M; Fuessel S; Nacke B; Arneth BM; Wirth MP; Siegert G
Exp Mol Pathol; 2013 Jun; 94(3):458-65. PubMed ID: 23541763
[TBL] [Abstract][Full Text] [Related]
12. Transcription levels of invasion-related genes in prostate cancer cells are modified by inhibitors of tyrosine kinase.
Skogseth H; Follestad T; Larsson E; Halgunset J
APMIS; 2006 May; 114(5):364-71. PubMed ID: 16725013
[TBL] [Abstract][Full Text] [Related]
13. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
14. NFkappaB-dependent regulation of urokinase plasminogen activator by proanthocyanidin-rich grape seed extract: effect on invasion by prostate cancer cells.
Uchino R; Madhyastha R; Madhyastha H; Dhungana S; Nakajima Y; Omura S; Maruyama M
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):528-33. PubMed ID: 20502321
[TBL] [Abstract][Full Text] [Related]
15. Amplification of urokinase gene in prostate cancer.
Helenius MA; Saramäki OR; Linja MJ; Tammela TL; Visakorpi T
Cancer Res; 2001 Jul; 61(14):5340-4. PubMed ID: 11454671
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells.
Henderson BR; Tansey WP; Phillips SM; Ramshaw IA; Kefford RF
Cancer Res; 1992 May; 52(9):2489-96. PubMed ID: 1568219
[TBL] [Abstract][Full Text] [Related]
17. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
Foca C; Moses EK; Quinn MA; Rice GE
Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652
[TBL] [Abstract][Full Text] [Related]
18. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
[TBL] [Abstract][Full Text] [Related]
19. Candidate host marker for peritoneal dissemination.
Hashizume K; Uchiyama A; Sasaki N; Noshiro H; Morisaki T; Tanaka M; Katano M
Anticancer Res; 2002; 22(3):1781-6. PubMed ID: 12168869
[TBL] [Abstract][Full Text] [Related]
20. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
